Table 1.
Detailed Characteristics of Included Studies.
| Author | Year | Country | Mean Age(year) | Sample Size | Follow-up period(months) | ND/RR | Stage | Detection methods | Outcome | NOS | Study design |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Markovic O | 2004 | Serbia | 63 | 59 | 29-36 | 59/0 | DS I-III | immunohistochemistry | OS | 6 | Prospective cohort study |
| Kelley TW | 2008 | USA | 59 | 94 | NR | 49/45 | SWOG stage l-IV | immunohistochemistry | OS/PFS | 7 | Prospective cohort study |
| Soverini S | 2003 | Italy | 53 | 74 | 9-64,34 | 74/0 | DS I-III | RT-PCR | EFS | 7 | Prospective cohort study |
| Cook JR | 2006 | USA | 58 | 44 | NR | 44/0 | NR | immunohistochemistry | OS/PFS | 9 | Prospective cohort study |
| Ngo BT | 2010 | Germany | 67 | 20 | NR | 0/20 | DS I-III | RT-PCR | OS/PFS | 7 | Retrospective cohort study |
| Pruneri G | 2008 | Italy | 64 | 128 | 27 | NR | DS I-III | immunohistochemistry | OS/PFS | 7 | Retrospective cohort study |
| Dawson MA | 2009 | Australia | 61 | 89 | 1-20,11 | 0/89 | NR | immunohistochemistry | OS | 8 | Prospective cohort study |
| Maillet D | 2012 | Mexico | 59 | 24 | 1-54 | 24/0 | NR | immunohistochemistry | OS | 6 | Prospective cohort study |
| Tasidou A | 2012 | Greece | 68 | 130 | 22 | 130/0 | ISS I-III | immunohistochemistry | OS | 8 | Prospective cohort study |
| Sewify EM | 2014 | Egypt | 59 | 50 | NR | NR | ISS I-III | FISH | OS/PFS | 7 | Retrospective cohort study |
| Rasmussen T | 2001 | Denmark | 62 | 76 | NR | 76/0 | DS I-III | RT-PCR | OS | 6 | Prospective cohort study |
| Hoechtlen-Vollmar | 2000 | Germany | 63 | 50 | 14 | 50/0 | DS I-III | immunohistochemistry | OS | 7 | Prospective cohort study |
| Inagaki A | 2013 | Japan | 68 | 123 | 24 | NR | DS I-III | RT-PCR | OS/PFS | 7 | Prospective cohort study |
Abbreviations: OS, overall survival; PFS, progression-free survival; EFS, event-free survival; NR, not report; ND, newly diagnosed; RR, relapsed/refractory; NOS, Newcastle-Ottawa scale.